Tag Archives: ASH 2024

EMA Committee Recommends Approval of Sarclisa-VRd Induction in Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant

(IN BRIEF) The CHMP has recommended EU approval of Sarclisa alongside VRd for transplant-eligible NDMM, based on GMMG-HD7 trial results showing superior MRD negativity and PFS compared to VRd alone. This potential label extension would mark Sarclisa’s fourth EU approval … Read the full press release

Roche Presents Promising Data on Bispecific Antibodies at ASH 2024, Highlighting Advancements in Lymphoma Treatment

(IN BRIEF) Roche presented new data at the ASH 2024 meeting highlighting the effectiveness of its bispecific antibodies, Columvi and Lunsumio, in treating lymphomas. Long-term studies show durable remissions and immune system recovery with fixed-duration therapies, while real-world data emphasize … Read the full press release